Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Drew Kern to Mutation

This is a "connection" page, showing publications Drew Kern has written about Mutation.

 
Connection Strength
 
 
 
0.224
 
  1. Mestre TA, Pont-Sunyer C, Kausar F, Visanji NP, Ghate T, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Faust-Socher A, Kasten M, Wadia PM, Zadikoff C, Kumar P, de Bie RM, Thomsen T, Lang AE, Schüle B, Klein C, Tolosa E, Marras C. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. Mov Disord. 2018 Jul; 33(6):960-965.
    View in: PubMed
    Score: 0.064
  2. van den Heuvel L, Lim AS, Visanji NP, Huang J, Ghate T, Mestre TA, AlDakheel A, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Pondal M, Faust-Socher A, Rogaeva E, Tomlinson G, Lang AE, Marras C. Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. J Parkinsons Dis. 2018; 8(1):131-139.
    View in: PubMed
    Score: 0.063
  3. Visanji NP, Bhudhikanok GS, Mestre TA, Ghate T, Udupa K, AlDakheel A, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Faust-Socher A, Kim S, Azhu Valappil R, Kausar F, Rogaeva E, William Langston J, Tanner CM, Schüle B, Lang AE, Goldman SM, Marras C. Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease. Mov Disord. 2017 04; 32(4):610-614.
    View in: PubMed
    Score: 0.059
  4. Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, Ghosh R, Maloney MT, Propson NE, Zhu Y, Maciuca RD, Harris L, Kay A, LeWitt P, King TA, Kern D, Ellenbogen A, Goodman I, Siderowf A, Aldred J, Omidvar O, Masoud ST, Davis SS, Arguello A, Estrada AA, de Vicente J, Sweeney ZK, Astarita G, Borin MT, Wong BK, Wong H, Nguyen H, Scearce-Levie K, Ho C, Troyer MD. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease. Sci Transl Med. 2022 06 08; 14(648):eabj2658.
    View in: PubMed
    Score: 0.021
  5. Arora S, Visanji NP, Mestre TA, Tsanas A, AlDakheel A, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Faust-Socher A, Lang AE, Little MA, Marras C. Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. J Parkinsons Dis. 2018; 8(4):503-510.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)